Vijiaratnam N, Girges C, Auld G, Chau M, Maclagan K, King A, Skene S, Chowdhury K, Hibbert S, Morris H, Limousin P, Athauda D, Carroll CB, Hu MT, Silverdale M, Duncan GW, Chaudhuri R, Lo C, Del Din S, Yarnall AJ, Rochester L, Gibson R, Dickson J, Hunter R, Libri V, Foltynie T
The other reason investors are questioning Novo Nordisks future is that it is not seen as having as strong of a pipeline of future drugs as its rivals, particularly Eli Lilly and some others
10.1038/s41380-020-0645-4 Mol Psychiatry
I guarantee you theres been no study of their particular product randomized to a large number of people demonstrating that that actually happens, said Cohen, whos investigated dietary supplement safety for decades
Small trials and case reports show promising short term results for select probiotics and short antibiotic courses
Overarching obesity management guidance prescribing orlistat, liraglutide and semaglutide (NG246)